What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly - CNBC

Wall Street progressively believes U.S. cause regulators volition o.k. Biogen's (BIIB) latest experimental Alzheimer's attraction pursuing the merchandise of elaborate late-stage objective proceedings data. It's a improvement that whitethorn transportation affirmative implications for Eli Lilly (LLY) due to the fact that the Club holding is investigating a akin cause targeting the disease.